Last reviewed · How we verify
Besivance (BESIFLOXACIN)
Besivance works by inhibiting bacterial DNA replication.
Besivance (Besifloxacin) is a quinolone antimicrobial small molecule developed by Bausch and Lomb. It is used to treat bacterial conjunctivitis, a bacterial infection of the eye. Besivance is FDA-approved and remains a patented product with no generic manufacturers. Key safety considerations include potential allergic reactions and eye irritation. As a quinolone antimicrobial, Besivance works by inhibiting bacterial DNA replication.
At a glance
| Generic name | BESIFLOXACIN |
|---|---|
| Sponsor | Bausch Health |
| Drug class | Quinolone Antimicrobial [EPC] |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2009 |
Mechanism of action
Besifloxacin is fluoroquinolone antibacterial [see Microbiology (12.4)].
Approved indications
- Bacterial conjunctivitis
Common side effects
- Conjunctival redness
Key clinical trials
- Besifloxacin in Bacterial Keratitis (NA)
- Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification (PHASE4)
- A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery (PHASE4)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery (PHASE1)
- Study of Ocular Penetration of Topically Administered Fluoroquinolones (PHASE4)
- Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children (PHASE1)
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Besivance CI brief — competitive landscape report
- Besivance updates RSS · CI watch RSS
- Bausch Health portfolio CI